Regeneron Pharmaceuticals, Inc.
REGNNASDAQHealthcareBiotechnology
As of Oct 23, 2026 close
- Market cap
- $85.33B
- P/E (TTM)
- 19.71
- Forward P/E
- 20.87
- Dividend yield
- 0.45%
- 52-week range
- $572.75$859.34
- Volume (live)
- -
- Avg. volume (3M)
- 731.62K
Regeneron Pharmaceuticals (REGN) Stock Price & Financial Analysis
Regeneron Pharmaceuticals Stock Price Chart
Loading chart...
Financial Metrics & Key Statistics
Fundamental metrics, valuation ratios, and profitability indicators
| Day's Range | $801.22 - $819.09 |
|---|---|
| 52-Week High | $859.34 |
| 52-Week Low | $572.75 |
| Open | $819.09 |
| Volume (last close) | 527.72K |
| Average Volume (3M) | 731.62K |
| Revenue (TTM) | 15.53B |
|---|---|
| Net Income (TTM) | 4.33B |
| Free Cash Flow (TTM) | 3.62B |
| EPS (TTM) | $40.42 |
| Profit Margin | 27.86% |
| Operating Margin | 26.21% |
| Return on Equity (ROE) | 13.65% |
| Debt to Equity | 0.06 |
| Annual Dividend | $3.70 |
|---|---|
| Dividend Yield | 0.45% |
| Payout Ratio | 9.15% |
| Last Dividend Ex-Date | Aug 18, 2026 |
| Market Cap | 85.33B |
|---|---|
| Shares Outstanding | 106.00M |
| P/E Ratio (TTM) | 19.71 |
| Forward P/E | 20.87 |
| Price to Sales (P/S) | 5.49 |
| Price to Book (P/B) | 2.69 |
| EV/EBITDA | 17.01 |
| 50-Day MA | $790.80 |
|---|---|
| 200-Day MA | $735.62 |
| 1-Year Change | +42.28% |
Source: Market prices and company fundamentals. Data as of Oct 23, 2026. Data sources and methodology
Regeneron Pharmaceuticals at a Glance
As of the Oct 23, 2026 close, Regeneron Pharmaceuticals (REGN) has a market capitalization of $85.33B. The stock trades at 19.7× trailing earnings, 20.9× forward earnings and 5.5× sales. Over the trailing twelve months it earned $4.33B on revenue of $15.53B (a 27.9% profit margin) and generated $3.62B of free cash flow. Revenue grew 9.3% year over year.
As of its latest reported balance sheet, it holds $2.46B in cash and securities against $1.99B of debt, a net cash position of $469.20M.
Regeneron Pharmaceuticals pays a quarterly dividend totaling $3.70 per share a year, a 0.45% yield at the Oct 23, 2026 close, with a 9% payout ratio.
The share price is up 42.3% over the past year. At $805.02 (the Oct 23, 2026 close) it sits within its 52-week range of $572.75 to $859.34, above its 200-day moving average of $735.62.
Based on 26 professional analyst ratings from the past 90 days, the consensus is Buy with an average price target of $863.45, 7.3% above the Oct 23, 2026 close.
Frequently Asked Questions About Regeneron Pharmaceuticals
What is the current stock price for REGN?
As of the Oct 23, 2026 close, REGN stock trades at $805.02. The 52-week range is $572.75–$859.34, with a day range of $801.22–$819.09.
What is the P/E ratio for REGN?
As of the Oct 23, 2026 close, Regeneron Pharmaceuticals's trailing twelve-month (TTM) P/E ratio is 19.7, meaning investors pay $19.7 for every $1 of annual earnings. The forward P/E is 20.9, reflecting analyst expectations for future earnings. Regeneron Pharmaceuticals operates in the Healthcare sector.
Does REGN pay dividends?
Yes, Regeneron Pharmaceuticals pays a 0.45% annual dividend yield as of the Oct 23, 2026 close ($3.70 per share a year). The trailing twelve-month payout ratio is 9.2%. The most recent ex-dividend date was August 18, 2026.
What do analysts recommend for REGN?
Based on ratings from 26 professional analysts over the last 90 days, the consensus for REGN is Buy. The average 12-month price target is $863.45, a 7.3% upside from the Oct 23, 2026 close of $805.02.
What is the market cap of REGN?
As of the Oct 23, 2026 close, Regeneron Pharmaceuticals's market capitalization is $85.33B, classifying it as a large-cap company. Regeneron Pharmaceuticals operates in the Healthcare sector within the Biotechnology industry.